XK
AIMT

Xact Kapitalforvaltning’s Aimmune Therapeutics AIMT Stock Holding History

Xact Kapitalforvaltning’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,100
Closed -$271K – 1396
2019
Q4 		$271K Buy
+8,100
New +$226K ﹤0.01% 1282
2018
Q4 		– Sell
-8,100
Closed -$221K – 1538
2018
Q3 		$221K Buy
+8,100
New +$229K ﹤0.01% 1500
2018
Q2 		– Sell
-6,500
Closed -$207K – 1596
2018
Q1 		$207K Buy
+6,500
New +$229K ﹤0.01% 1473

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Xact Kapitalforvaltning's AIMT Position: Q1 2020 in Review

Xact Kapitalforvaltning sold out of Aimmune Therapeutics (AIMT) in Q1 2020, closing a stake of 8,100 shares — an estimated $271K sold.

Xact Kapitalforvaltning first reported a position in AIMT in Q1 2018 and held it in 3 quarters. The position peaked at $271K in Q4 2019. 161 funds tracked by Wall St. Rank hold AIMT as of Q1 2020.

  • Xact Kapitalforvaltning reported no remaining Aimmune Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Xact Kapitalforvaltning sold 8,100 Aimmune Therapeutics shares in Q1 2020, an estimated $271K.
  • Xact Kapitalforvaltning first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 3 quarters.
  • Xact Kapitalforvaltning's Aimmune Therapeutics position peaked at $271K in Q4 2019.
  • 161 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.